Connectome dysfunction in patients at clinical high risk for psychosis and modulation by oxytocin.
Davies C., Martins D., Dipasquale O., McCutcheon RA., De Micheli A., Ramella-Cravaro V., Provenzani U., Rutigliano G., Cappucciati M., Oliver D., Williams S., Zelaya F., Allen P., Murguia S., Taylor D., Shergill S., Morrison P., McGuire P., Paloyelis Y., Fusar-Poli P.
Abnormalities in functional brain networks (functional connectome) are increasingly implicated in people at Clinical High Risk for Psychosis (CHR-P). Intranasal oxytocin, a potential novel treatment for the CHR-P state, modulates network topology in healthy individuals. However, its connectomic effects in people at CHR-P remain unknown. Forty-seven men (30 CHR-P and 17 healthy controls) received acute challenges of both intranasal oxytocin 40 IU and placebo in two parallel randomised, double-blind, placebo-controlled cross-over studies which had similar but not identical designs. Multi-echo resting-state fMRI data was acquired at approximately 1 h post-dosing. Using a graph theoretical approach, the effects of group (CHR-P vs healthy control), treatment (oxytocin vs placebo) and respective interactions were tested on graph metrics describing the topology of the functional connectome. Group effects were observed in 12 regions (all pFDR